, the successes to date have validated the simple principle that if you understand it you can fix it. For cancer therapeutics this idea is widely accepted today and is supported by massive investments in this approach by pharmaceutical and biotechnology firms. However, while few would argue with the idea that preventing cancer is better than treating it, investigators in the field of cancer prevention have not particularly warmed to the notion that the molecular strategies used for developmental therapeutics can support their goals as well. This situation has to change because there is clear-cut experimental evidence that the earliest control points for carcinogenic change in stem cells can be identified by focusing on stem cell pools under stress. The natural implication is that by interdicting this stress one might prevent the evolution of neoplastic clones.
Stressed stem cell pools are vulnerable to neoplastic change
Most leukemias evolve as clonal outgrowths of single, somatically mutated HSCs. Studies of patients with inherited bone marrow failure syndromes (Table 1) , in which the HSCs are either constitutively proapoptotic or hypersensitive to apoptotic cues, suggest that the apoptotic state itself represents a selective pressure that favors the evolution of neoplastic clones. The apoptotic cues that put these "unfit" (in the Darwinian sense) HSCs at risk have not been fully defined in these inherited syndromes, but in the case of the inherited bone marrow failure syndrome Fanconi anemia (FA), sufficient evidence has developed to identify TNF-α as one of the key pathophysiological factors influencing clonal evolution in FA HSCs (2) .
Up to 40% of children and young adults with FA (3, 4) will exhibit signs of clonal evolution in the bone marrow, a process in which somatically mutated HSCs selfreplicate and give rise to progeny that overtake the bone marrow, leading to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Prior to the onset of clonal evolution, HSCs and committed progenitor cells from the bone marrow of patients bearing inactivating mutations of two FA complementation group C (FANCC) alleles undergo apoptosis in response to a variety of cytokines (including TNF-α) at very low doses - doses that have no capacity to suppress proliferation and survival of normal progenitors (5, 6). In both murine models and in humans with FA, when clonal progeny of somatically mutated stem cells appear in the marrow, the clones are resistant to TNF-α (2, 7, 8) . These results suggested that clonal progeny have ascended either by selection of preexisting covert mutant stem cells (9) or through adaptive mutations that occur during selective sweeps of TNF-α through the HSC pool.
A few months ago, in this journal, Li et al. (2) reported a model of induced clonal selection in which FA HSCs exposed to TNF-α gave rise to cytogenetically abnormal neoplastic clones ex vivo in a matter of 4-5 weeks. That is, the progeny of a more fit somatically mutated stem cell replaced those of the less fit FA cells because this single stem cell had adapted to the troublesome apoptotic cue. Our expectation that this general model will hold true for some of the other inherited bone marrow failure syndromes is supported by the report in mice from Liu, Link, and colleagues in this issue of the JCI (10) , which suggests that the model is applicable to HSCs in the marrow of patients with the inherited bone marrow failure state known as severe congenital neutropenia (SCN).
Clonal evolution in SCN
SCN is a genetically heterogeneous inherited disease frequently associated with mutations of the neutrophil elastase 2 (ELA2) gene (11) . Patients are reliably responsive to pharmacological doses of G-CSF, an agent that clearly reduces morbidity and mortality in children with this disease. The molecular mechanisms linking ELA2 mutations to failure of granulopoiesis are unclear, although it has been reported that myeloid precursor cells are highly apoptotic owing to constitutive activation of the unfolded protein response in cells bearing ELA2 mutations (12, 13) . As is the case with most other inherited bone marrow failure syndromes, the relative risk of AML or MDS is high in SCN (see Table 1 ). Interestingly, truncating mutations of the G-CSF receptor are common in SCN patients (14) and are positively associated with clonal evolution to AML and MDS (15) . It had been known for a number of years that this type of mutation resulted in conditional hyperactivation of the G-CSF receptor and resistance to apoptosis in myeloid cells (16).
It was not known, however, whether these activating mutations of the G-CSF receptor played any role in changing the coefficient of selection, specifically in the HSC pool, an important requirement for early leukemogenic mutations. In their current study, Liu, Link, and colleagues (10) used a murine model in which HSCs expressed a truncating mutation of the G-CSF receptor (also known as Csf3r) to demonstrate that exogenous G-CSF permitted the mutant clone to dominate in competitive repopulation experiments. The G-CSF receptor possessing the mutation was not capable of functioning autonomously. That is, exogenous G-CSF was absolutely required. These authors also found that the transcription factor Stat5, known to be activated in normal cells by G-CSF, was absolutely required for the mutant HSCs to be efficient competitive repopulators, a finding that itself clarifies a number of prior uncertainties on the role of STAT5 in HSCs. Clones bearing the mutant receptor did not evolve to AML or MDS in the current study; a finding that recapitulates the human disease in which even highly clonal hematopoiesis does not inevitably progress to leukemia (15) . Therefore, studies on the evolution of this mutation in humans and the obvious consequences of the mutation in mice strongly suggest that the G-CSF receptor mutation is an early event in leukemogenesis.
The role of HSC damage in clonal evolution
The results of this nicely designed study (10) begin to place clonal evolution in SCN in the same category as clonal evolution in FA. In both conditions HSCs are highly apoptotic, a perfect microenvironmental setting for the selection of stem cell clones that have, as a result of somatic mutations or epigenetic changes, acquired resistance to factors in the microenvironment that injure them. In both settings, the somatically mutated HSCs have a high coefficient of selection because the somatic mutation enhanced the relationship of the HSC with its microenvironment. In the case of FA HSCs, new clones escape cell death by interdicting apoptotic responses to TNF-α, precisely the environmental cue to which the unevolved FA HSCs are hypersensitive (2) . In patients with SCN, neoplastic HSCs emerge as a result of a G-CSF receptor mutation. This implies, of course, that the HSC pool in SCN bone marrow is responding suboptimally to endogenous G-CSF levels. In SCN and FA the pressure for the emergence of more fit stem cells results in the selection of clones that are better adapted for survival in their respective microenvironments (Figure 1 ). The adaptive responses can occur in two ways. Rarely, mutant FA HSCs correct the inherited mutation on one of two mutant alleles. This results in clonal reversion (mosaicism) (17) and, in some cases, complete resolution of bone marrow failure (18) . The second pathway of adaptation reflects a kind of molecular "work around" and aberrant activation of antiapoptotic programs. This second adaptive pathway is more maladaptive with respect to the whole patient because the clonal progeny are too resistant to apoptotic cues for their own good. They survive when a normal cell would have reasons not to (for example, when high-level genetic damage should induce apoptotic responses). These mutant cells are more apt to suffer a concatenation of additional mutations and are therefore more likely to evolve to frank leukemic stem cell clones.
The results reported in this issue by Liu et al. (10) help to define some unique
Figure 1
The selection coefficient in HSC pools influences clonal evolution. Potentially leukemogenic translocations can be found in normal individuals who do not go on to develop leukemia (9) . Shown here are somatically mutated HSCs (black) in the context of normal bone marrow (normal HSCs are shown in gray) and in the bone marrow of a patient with an inherited bone marrow failure syndrome (genetically unfit HSCs are shown in red). The coefficient of selection for the somatically mutated HSC in normal hematopoiesis is low so the mutant HSC is not significantly more fit. However, when the large population of HSCs is genetically unfit, the same mutant clone has a better opportunity to gain a foothold. Here, the somatically mutated HSCs in the normal and abnormal hematopoietic states have precisely the same mutation. The somatic mutant HSC in the company of the genetically unfit HSCs has a higher selection coefficient, not because of an autonomous attribute, but because the surrounding stem cells are highly unfit. The unfit HSCs are purged from the bone marrow (t1) and are replaced by the progeny of the somatic mutant (this population expands at t2). The data reported in this issue of the JCI by Liu et al. (10) demonstrate that the truncation G-CSF receptor mutation is capable of influencing the expansion of HSCs in the context of G-CSF treatment in mice. Although key studies remain to be performed in human cells, the results do provide a likely pathophysiological mechanism (G-CSF-induced STAT5 activation via a conditionally mutated receptor) for clonal HSC expansion in patients with SCN, expansions that seem to be required very early in the leukemogenic process. t, time.
investigative opportunities. For example, whether the ELA2 mutation interferes with G-CSF signaling specifically in HSCs should be tested directly. Positive results would explain how the coefficient of selection for G-CSF receptor mutations would be sufficiently high to account for clonal evolution in vivo. Secondly, because activated STAT5 multimerizes and then translocates to the nucleus to function as a transcription factor, experimentally defining promoter binding sites unique to stem cells bearing the G-CSF receptor mutation may help identify gene products that directly enhance stem cell fitness. Third, experiments on clonal progeny that have evolved without a G-CSF receptor mutation might be targeted to factors that modulate G-CSF activity. For example, might loss-of-function mutations involving suppressors of cytokine signaling (19) be involved in these less frequent cases? Most importantly, by defining the full scope and order of adaptive somatic mutations we can begin to contemplate experiments designed to enhance HSC fitness, thereby reducing the likelihood of clonal selection of potentially neoplastic stem cells. It is time to exploit the investigative strategies that have so nicely served developmental therapeutics teams and turn the methods to a bold new aim - molecularly targeted leukemia prevention for patients at high risk.
